drug · protein
survodutide
Phase 3updated 5mo agoby Boehringer Ingelheim International GmbH🔗 ChEMBL
Phase 3community read0 votes
Protein drug with a maximum clinical stage of Phase 3 (across all indications), with 5 investigational indications.
targets
Glucagon-like peptide 1 receptorGlucagon receptor
all catalysts(0)
nothing on the calendar yet
Trials studying survodutide
- phase3A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)
- phase3A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
- phase3LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
- phase1A Study in Healthy People or Otherwise Healthy With Overweight or Obesity to Compare 2 Formulations of Survodutide Given in Different Ways, Either as a Pre-filled Syringe or a Pen-like Injector
- phase3LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
- phase3A Study to Test Whether Survodutide Helps Japanese People Living With Obesity Disease
- phase3A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight
- phase1A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity
News(7)
- 3 takeaways from a European obesity scientific meetingEli Lilly impressed with its amylin-Zepbound combination data. Elsewhere, Novo demonstrated continued weight loss following a switch to oral and AbbVie and Boehringer gave glimpses into their conte…biopharma_dive · 3d ago
- Zealand dips as Boehringer Ingelheim-partnered weight loss drug fails to impress—againDespite meeting the primary endpoints in a Phase 3 trial, shares of Zealand Pharma dropped in premarket trading Thursday as the up to 9.8% weight loss reflected inferior loss to that generated by c…biospace · 3d ago
- Zealand's stock slides as Boehringer-partnered obesity drug underwhelms again in phase 3A phase 3 trial of Boehringer Ingelheim’s survodutide in people with obesity and Type 2 diabetes has met its co-primary endpoints. Yet, with the readout echoing earlier data that underwhelmed analy…fiercebiotech · 3d ago
- Zealand sells its rights to Takeda’s blood cancer drug for $100M ahead of FDA approval decisionAs the FDA mulls whether to approve Takeda and Protagonist Therapeutics’ rusfertide, Zealand Pharma has sold its own rights to the blood cancer drug in return for $100 million.fiercebiotech · 1mo ago
- #ADA26: 19% of Phase 3 patients quit Boehringer obesity shot over side effectsBoehringer Ingelheim’s obesity asset survodutide, which it licensed from Zealand Pharma, has shown high rates of discontinuations in its Phase 3 obesity study. In April, data from the SYNCHRONIZE-1…endpoints · 3mo ago
- STAT+: New data may cast doubt on competitiveness of Boehringer’s obesity drugBoehringer Ingelheim’s obesity drug showed promise in cutting liver fat, but it was less impressive at overall weight loss, new data shows.stat · 3mo ago
- Boehringer dual-acting obesity shot hits mark in Phase 3 trialSurvodutide spurred weight loss Wall Street analysts referred to as “Wegovy-like,” and showed signs it might help preserve muscle mass as well.biopharma_dive · 5mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that